Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Grrrrrr! Update

$Theratechnologies(THTX.US)$ •FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024
MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received correspondence from the U.S. Food and Drug Administration (FDA) regarding the Company's supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin. The FDA has notified the Company that it is continuing its review of the application beyond the Prescription Drug User Fee Act (PDUFA) goal date of January 22, 2024. Further information will be provided in due course.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
4
Translate
Report
2574 Views
Comment
Sign in to post a comment
1937Followers
30Following
23KVisitors
Follow